Lilly appoints life scientist to board of directors

Pharmaceutical Company Restructures

Lilly has announced the appointment of Professor Carolyn Bertozzi as a new member of its board of directors, effective as of today (February 10th 2017).

As a member of Lilly's board, Professor Bertozzi will serve on the company's science and technology and public policy and compliance committees.

“Lilly has appointed life science expert Professor Carolyn Bertozzi as the newest member of its board of directors.“

She currently serves as professor of chemistry and of chemical and systems biology and radiology at Stanford University, while also acting as an investigator for the Howard Hughes Medical Institute.

Her research interests numerous fields within chemistry and biology, with a specific emphasis on studies of cell surface glycosylation pertinent to disease states. The professor's lab focuses on profiling changes in cell surface glycosylation associated with cancer, inflammation and bacterial infection.

Over the course of her career, Professor Bertozzi has received numerous awards for her research accomplishments, including the Lemelson-MIT Prize, the Heinrich Wieland Prize and a MacArthur Foundation Fellowship.

Dr John Lechleiter, chairman of the board of directors at Lilly, said the new board member "will contribute greatly to our board and our company as we seek to advance Lilly's pipeline of potential new medicines to benefit patients and our other key stakeholders".

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.

See all the latest jobs in Pharmaceutical
Return to news

Tags